Retatrutide 15mg

Buy Retatrutide 15 mg 

Retatrutide 15 mg, also known as LY3437943, is an investigational synthetic peptide developed by Eli Lilly and Company. Retatrutide is a triple receptor agonist that activates GIP, GLP-1, and glucagon receptors. This multi-receptor activity makes it an important research compound for studying incretin signaling, glucagon biology, energy metabolism, and metabolic regulation. 

Research on retatrutide has progressed from early-stage studies to large Phase 3 programs. In the 2023 Phase 2 trial published in the New England Journal of Medicine, researchers evaluated several once-weekly doses, including doses up to 12 mg, and reported dose-dependent changes in body weight and metabolic measures over 48 weeks.

More recent development has moved into Phase 3 research. In 2026, Lilly reported positive results from several Phase 3 studies, including TRIUMPH-1, TRIUMPH-2, and TRANSCEND-T2D-1. TRIUMPH-1 evaluated retatrutide in adults with obesity, while TRIUMPH-2 examined participants with obesity or overweight and type 2 diabetes. These studies continue to provide data on the pharmacology and effects of triple-receptor activation.

For laboratory research, Retatrutide 15 mg can be used as a research material for investigating GIP/GLP-1/glucagon receptor signaling, peptide pharmacology, endocrine pathways, and metabolic research models. It should be noted that the specific 15 mg research formulation is not itself the subject of the major clinical trials, which evaluated defined clinical doses and formulations.

Research Use Only: This product and all other available product at Sequora Peptides, are intended exclusively for laboratory research. It is not intended for human or veterinary use, diagnosis, treatment, or prevention of disease.

Selected Research Papers

1. Jastreboff AM, et al. (2023). Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. New England Journal of Medicine, 389, 514–526.
   DOI: 10.1056/NEJMoa2301972.
2. Rosenstock J, et al. (2023). Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist, for People with Type 2 Diabetes. The Lancet, 402, 529–544.
   DOI: 10.1016/S0140-6736(23)01053-X.
3. Urva S, et al. (2022). LY3437943, a Novel Triple GIP, GLP-1, and Glucagon Receptor Agonist in People with Type 2 Diabetes. The Lancet, 400, 1869–1881.
   DOI: 10.1016/S0140-6736(22)02033-5.
4. Jastreboff AM, et al. / TRIUMPH-1 (2026). The First Phase 3 Obesity Study of Retatrutide, a GIP, GLP-1 and Glucagon Receptor Agonist. The study reported substantial dose-dependent changes in body weight at 80 weeks, including results for the 12 mg group.